Genix Pharmaceuticals Corporation
GENX.V
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -275.55% | -134.88% | -341.70% | 97.96% | 98.03% |
| Total Depreciation and Amortization | -- | -- | -- | -100.60% | -100.20% |
| Total Amortization of Deferred Charges | -66.67% | -40.00% | 0.00% | 75.00% | 50.00% |
| Total Other Non-Cash Items | 260.35% | 236.83% | 220.64% | -102.96% | -103.24% |
| Change in Net Operating Assets | -41.64% | 17.93% | 7.80% | 278.63% | 357.80% |
| Cash from Operations | 41.48% | 56.97% | 36.89% | 38.38% | 26.83% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -73.42% | -83.89% | -53.34% | -38.68% | -11.26% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -29.41% | -50.20% | -18.97% | -41.69% | -16.00% |
| Foreign Exchange rate Adjustments | -507.69% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 225.00% | 261.90% | 23,400.00% | -188.64% | 84.48% |